

I. Requirements for Prior Authorization of Anticonvulsants

A. <u>Prescriptions That Require Prior Authorization</u>

Prescriptions for Anticonvulsants that meet any of the following conditions must be prior authorized:

- 1. A non-preferred Anticonvulsant. See the Preferred Drug List (PDL) for the list of preferred Anticonvulsants at: https://papdl.com/preferred-drug-list.
- 2. A prescription for clonazepam when prescribed for a beneficiary under 21 years of age.
- 3. A prescription for clonazepam when there is a record of a recent paid claim for another benzodiazepine (excluding clobazam and benzodiazepines indicated for the acute treatment of increased seizure activity [e.g., rectal and nasal formulations]) (therapeutic duplication).
- 4. A prescription for a clonazepam when there is a record of 2 or more paid claims for any benzodiazepine (excluding clobazam and benzodiazepines indicated for the acute treatment of increased seizure activity [e.g., rectal and nasal formulations]) within the past 30 days.
- 5. A prescription for clonazepam when a beneficiary has a concurrent prescription for a buprenorphine agent indicated for the treatment of opioid use disorder.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Anticonvulsant, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

- 1. For a non-preferred Anticonvulsant, **one** of the following:
 - a. Has a current history (within the past 90 days) of being prescribed the same non-preferred Anticonvulsant (does not apply to non-preferred brands when the therapeutically equivalent generic is preferred or to non-preferred generics when the therapeutically equivalent brand is preferred)
 - b. **All** of the following:
 - i. **One** of the following:
 - a) For a diagnosis of a seizure disorder, has a documented history of therapeutic failure of or a contraindication or an intolerance to **two** preferred Anticonvulsants approved or medically accepted for the beneficiary's diagnosis (therapeutic failure of preferred Anticonvulsants must include the generic equivalent when the generic equivalent is designated as preferred)



- b) For all other diagnoses, has a documented history of therapeutic failure of or a contraindication or an intolerance to the preferred Anticonvulsants approved or medically accepted for the beneficiary's diagnosis (therapeutic failure of preferred Anticonvulsants must include the generic equivalent when the generic equivalent is designated as preferred),
- Is being treated for a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication,
- iii. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature,
- iv. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature;

AND

- 2. For clonazepam, all of the following:
 - a. For a beneficiary under 21 years of age, **one** of the following:
 - i. Has a diagnosis of **one** of the following:
 - a) Seizure disorder,
 - b) Chemotherapy induced nausea and vomiting,
 - c) Cerebral palsy,
 - d) Spastic disorder,
 - e) Dystonia,
 - f) Catatonia
 - ii. Is receiving palliative care,
 - b. For a beneficiary with a concurrent prescription for a buprenorphine agent indicated for the treatment of opioid use disorder, **both** of the following:
 - Is prescribed the buprenorphine agent and clonazepam by the same prescriber or, if prescribed by different prescribers, all prescribers are aware of the other prescription(s)
 - ii. Has an acute need for therapy with clonazepam,
 - c. For therapeutic duplication of clonazepam with another benzodiazepine, **one** of the following:
 - i. Is being titrated to or tapered from another benzodiazepine
 - ii. Has a medical reason for concomitant use of the requested medications that is supported by peer-reviewed medical literature or national treatment guidelines,





- d. When there is a record of 2 or more paid claims for any benzodiazepine, **both** of the following:
 - The multiple prescriptions are consistent with medically accepted prescribing practices and standards of care, including support from peer-reviewed medical literature or national treatment guidelines
 - ii. The multiple prescriptions are written by the same prescriber or, if written by different prescribers, all prescribers are aware of the other prescription(s),
- e. One of the following:
 - i. Meets the guidelines in B.2.a.
 - Has documentation that the prescriber or the prescriber's delegate conducted a search of the Pennsylvania Prescription Drug Monitoring Program (PDMP) for the beneficiary's controlled substance prescription history;

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Anticonvulsant. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.





Prescriber Signature:

BENZODIAZEPINES PRIOR AUTHORIZATION FORM

	DLI	VEODITIES IN	OK MOTHORIZA	HOW FOR	<u>v i</u>						
☐New request	☐Renewal request	# of pages:	Prescriber name:								
Name of office contact	Specialty:										
Contact's phone num	NPI:			State license #:							
LTC facility contact/pl	Street address:										
Beneficiary name:	Suite #: City/State/Zip:										
Beneficiary ID#:		DOB:	Phone:			Fax:					
CLINICAL INFORMATION											
Benzodiazepine requ	Strength: Dosage form (capsule, tablet, etc.):			let, etc.):							
Directions:	Quar		Quant	ity:	Refills:						
Diagnosis (submit do			Dx co	de (<u>required</u>):							
If the requested benzodiazepine is non-preferred, did the beneficiary try and fail the preferred benzodiazepines approved or medically accepted for the treatment of their condition? <i>Refer to</i> https://papdl.com/preferred-drug-list for the list of preferred and non-preferred drugs.					□Ye:	☐Yes – S <i>ubmit documentation.</i> ☐No					
Was a search of the F	Prescription Drug Monitorin	ng Program (PDMP) complete	d by the prescribing office?		☐Ye:	Yes					
beneficiary and this request and SUBMIT DOCUMENTATION for each. The beneficiary is under 21 years of age and: Has a diagnosis of: seizure disorder chemo-induced nausea/vomiting cerebral palsy spastic disorder dystonia catatonia palliative care Does not have one of the diagnoses listed above and is not receiving palliative care and: Use of the requested benzodiazepine for a person <21 years of age is supported by national treatment guidelines or medical literature the beneficiary has tried other treatments for their condition – list: The beneficiary is taking 2 or more different benzodiazepines concurrently (therapeutic duplication) and: Concomitant use of the benzodiazepines is supported by national treatment guidelines or medical literature lis being titrated to or tapered from one of the benzodiazepines The beneficiary filled 2 or more prescriptions for any benzodiazepine in the past 30 days and: The prescriptions are for the same benzodiazepine, strength, and directions Each prescription was filled for <30 days' supply											
□ Other reason for filling >1 benzodiazepine prescription in the past 30 days – specify:											
P	LEASE FAX CUMPLE	LIED FUKINI IU HIGHINI	AKK WHULEUA	AKE - PH/	HKIVI	ACT DIVISION					

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.



It's Wholecare.

Gateway Health Plan Pharmacy Division Phone 800-392-1147 Fax 888-245-2049

NON-PREFERRED MEDICATION PRIOR AUTHORIZATION FORM (form effective 01/01/20)

New request	Renewal request	# of pages:	Prescriber name:									
Name of office conta	Specialty:											
Contact's phone nui	NPI:			State license #:								
LTC facility contact/	Street address:											
Beneficiary name:	Suite #:	City/State/Zip:										
Beneficiary ID#:		DOB:	Phone:			Fax:						
Please refer to https://papdl.com/preferred-drug-list for the list of preferred and non-preferred medications in each Preferred Drug List class.												
Non-preferred medication name:			Dosage form: Strength:									
Directions:					Quan		Refills:					
Diagnosis (submit d	locumentation):					ode (<i>required</i>):						
			Yes	□No								
Has the beneficiary taken the requested non-preferred medication in the past 90 days? (submit documentation)												
Unacceptable side effects, hypersensitivities, or other intolerances to preferred medication(s) (include description and drug name(s)):												
Contraindication to preferred medication(s) (include description and drug name(s)):												
Unique clinical or age-specific indications supported by FDA approval or medical literature (describe):												
Absence of preferred medication(s) with appropriate formulation (list medical reason formulation is required):												
☐Drug-drug intera	ction with preferred media	cation(s) (describe):										
Other medical reason(s) the beneficiary cannot use the preferred medication(s) (describe):												
For renewal requests of previously approved medications, submit documentation of tolerability and beneficiary's clinical response.												
PLEASE FAX COMPLETED FORM TO HIGHMARK WHOLECARE – PHARMACY DIVISION												
Drescriber Signatu	ıro.				Da							

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.